Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer.

Abstract

Docetaxel demonstrates significant activity in patients with platinum-refractory advanced ovarian cancer. Routine premedication is recommended. Further investigations of this agent in ovarian cancer, including combinations with other active agents, appear indicated.